Leap Therapeutics Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>LT</div>
Leap Therapeutics is scheduled to announce its earnings tomorrow. The next earnings report is expected on the 12th of November 2020. While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to break down Leap Therapeutics under the current economic conditions. We will evaluate why recent Leap Therapeutics price moves suggest a bounce in September.
Published over a month ago
View all stories for Leap Therapeutics | View All Stories
Should you exit your Leap Therapeutics (NASDAQ:LPTX) positions following the current analyst consensus?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Leap Therapeutics has an asset utilization ratio of 9.23 percent. This suggests that the company is making $0.0923 for each dollar of assets. An increasing asset utilization means that Leap Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.

What is happening with Leap Therapeutics this year

Annual and quarterly reports issued by Leap Therapeutics are formal financial statements that are published yearly and quarterly and sent to Leap Therapeutics stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Leap Therapeutics often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Leap Therapeutics utilizes its cash?

To perform a cash flow analysis of Leap Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Leap Therapeutics is receiving and how much cash it distributes out in a given period. The Leap Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Leap Therapeutics Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Leap Therapeutics reported Net Cash Flow from Operations of (26.9 Million) in 2019

Leap Therapeutics exotic insider transaction detected

Legal trades by Leap Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Leap Therapeutics insider trading alert for general transaction of employee stock option (right to buy) by Granfield Christine, VP Head of Reg AffairsQual, on 21st of August 2020. This event was filed by Leap Therapeutics Inc with SEC on 2020-08-21. Initial filing of beneficial ownership - SEC Form 3 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Leap Therapeutics a risky opportunity?

Let's check the volatility. Leap Therapeutics is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Leap Therapeutics (NASDAQ:LPTX) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of a Leap Therapeutics stock makes you a part-owner of that company.

Leap Therapeutics Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Leap Therapeutics. The Leap Therapeutics consensus assessment is calculated by taking the average estimates from all of the analysts covering Leap Therapeutics

Strong Buy
4
Buy
1
Strong Buy480.0
Buy120.0
Hold00.0
Sell00.0
Strong Sell00.0

Leap Therapeutics has 80 percent likelihood to hit $1.94 in September

Current Information Ratio is up to -0.08. Price may slide again. Leap Therapeutics exhibits very low volatility with skewness of -0.06 and kurtosis of 2.7. However, we advise investors to further study Leap Therapeutics technical indicators to make sure all market info is available and is reliable.

Our Final Take On Leap Therapeutics

While few other entities in the biotechnology industry are either recovering or due for a correction, Leap Therapeutics may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Leap Therapeutics valuation and our trade advice on Leap Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Leap Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Leap Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com